• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Achilles Therapeutics Plc (NQ: ACHL )

    0.8300 -0.0100 (-1.19%)
    Streaming Delayed Price Updated: 1:28 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,959
    Open 0.8400
    Bid (Size) 0.8200 (14)
    Ask (Size) 0.8400 (195)
    Prev. Close 0.8400
    Today's Range 0.8300 - 0.8480
    52wk Range 0.7400 - 1.760
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
    ACHL stock results show that Achilles Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -4.82%
    -4.82%
    1 Month
    -2.81%
    -2.81%
    3 Month
    +5.06%
    +5.06%
    6 Month
    -0.62%
    -0.62%
    1 Year
    -19.42%
    -19.42%

    More News

    Read More
    Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Achilles Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
    Via ACCESSWIRE
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    Via Investor Brand Network
    Exposures Product Safety
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    Via FinancialNewsMedia
    Exposures Product Safety
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics to Present at Upcoming Conferences
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    3 Stocks With 1,000% Upside Potential
    Via InvestorPlace
    Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
    From Achilles Therapeutics PLC
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.